To determine whether AURKB inhibition influences the progression of established and ongoing pulmonary fibrosis following 3 weeks of Dox treatment when fibrosis is already manifest, TGFα mice were administered barasertib while remaining on Dox for an additional 3 weeks (Fig 7A). This evidence concerns the gene AURKB and pulmonary fibrosis.